Compound: Refametinib

Drug Target: MEK1, MEK2

Drug Target pathway: ERK MAPK signaling

Dataset



Tissue specific analysis

Contact us | Cookies policy | Terms & Conditions. This site is hosted by the Wellcome Sanger Institute.